Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.
AbbVie touts Skyrizi ulcerative colitis data as it eyes another indication
AbbVie has touted Skyrizi as a key pillar of its future beyond Humira, and on Thursday, the company read out results suggesting the IL-23 inhibitor